Show all
  • Eugene P. Kennedy, MD, FACS, is Chief Medical Officer at NewLink Genetics, where he leads clinical development across all immuno-oncology product candidates as well as investigator initiated trials. Prior to joining NewLink Genetics, he was on faculty and clinical staff at Thomas Jefferson University in Philadelphia, Pennsylvania where he served as associate professor of Surgery and held leadership positions as chief of the Section of Pancreaticobiliary Surgery and co-director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Previously, Dr Kennedy held faculty positions at Johns Hopkins Hospital in Baltimore, Maryland, and the Louisiana State University School of Medicine in New Orleans, Louisiana. He has considerable experience in clinical trial design and implementation, leading both investigator initiated and industry sponsored efforts.

    • Carl Langren has served as NewLink Genetics’ Chief Financial Officer since July 2018. Previously, he was Vice President of Finance of NewLink, Chief Financial Officer of BioProtection Systems, Housby Mixer Group, and Equity Dynamics, Inc. He served as a Principal in Capital Management Solutions, President of Iowa Machinery and Supply, Treasurer of DFM Corporation, and Tax Manager with McGladrey Pullen and Company.

      Carl received a BA in accounting from the University of Iowa in Iowa City, Iowa.

      Stock transaction information provided by EDGAR Online. NewLink Genetics Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating, or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.